DZD9008 (Sunvozertinib) is an oral, potent, irreversible, wild type-selective EGFR inhibitor against EGFR or HER2 Exon20ins and other mutations with IC50 ranging from 0.4 nM to 2.1 nM for mutant EGFR.
[1] Yan Xu, et al. Cancer Research. Experimental and Molecular Therapeutics. AM2019-3081 Published July 2019
















